Publications by authors named "Suneel Mundle"

Claim this Profile
S
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).
Benjamin L Maughan, Yanfang Liu, Suneel Mundle, Xiayi Wang, Mehregan Nematian-Samani

Prostate Cancer Prostatic Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, Shahneen Sandhu, Eleni Efstathiou, Suneel D Mundle

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN.
Alejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, Alvaro Juarez Soto, Beatriz Garcillan, Suneel D Mundle

Eur Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan).
Masaki Shiota, Yanfang Liu, Suneel Mundle, Mehregan Nematian-Samani, Jason Hwang

Sci Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
Ding-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, Hiroyoshi Suzuki, Suneel Mundle

Int J Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study.
Stephen J Freedland, Luis Fernandes, Francesco De Solda, Nasuh Buyukkaramikli, Suneel D Mundle

Target Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
Benjamin A Gartrell, Angaja Phalguni, Paulina Bajko, Suneel D Mundle, Sharon A McCarthy

Eur Urol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
Axel S Merseburger, Neeraj Agarwal, Anders Bjartell, Hirotsugu Uemura, Alvaro Juarez Soto, Suneel D Mundle

BJU Int· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eric J Small, Kim N Chi, Simon Chowdhury, Katherine B Bevans, Amitabha Bhaumik, Suneel D Mundle

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.
Yoshitaka Honma, Nobuya Monden, Keisuke Yamazaki, Satoshi Kano, Hironaga Satake, Suneel Mundle

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
Pär Stattin, Sarah Fleming, Xiwu Lin, Florence Lefresne, Sabine D Brookman-May, Suneel D Mundle

BJU Int· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, Jeremie Calais, Johannes Czernin, Suneel D Mundle

Eur Urol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Simon Chowdhury, Anders Bjartell, Neeraj Agarwal, Byung H Chung, Robert W Given, Suneel D Mundle

Future Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
John Shen, Simon Chowdhury, Neeraj Agarwal, Lawrence I Karsh, Stéphane Oudard, Suneel D Mundle

Br J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Suneel D Mundle

Prostate Cancer Prostatic Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients.
Stephen J Freedland, Sandhya Nair, Xiwu Lin, Lawrence Karsh, Christopher Pieczonka, Suneel D Mundle

World J Urol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
Byung Ha Chung, Jian Huang, Hiroji Uemura, Young Deuk Choi, Zhang-Qun Ye, Suneel Mundle

Asian J Androl· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Axel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, Florence Lefresne, Laurence I Karsh, Suneel D Mundle

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Suneel D Mundle

Prostate Cancer Prostatic Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Hirotsugu Uemura, Gaku Arai, Hiroji Uemura, Hiroyoshi Suzuki, Junya Aoyama, Suneel Mundle

Int J Urol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
Byung Ha Chung, Jian Huang, Zhang-Qun Ye, Da-Lin He, Hirotsugu Uemura, Suneel Mundle

Asian J Androl· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Fred Saad, Eric J Small, Felix Y Feng, Julie N Graff, David Olmos, Suneel D Mundle

Eur Urol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
Giulia Baciarello, Mustafa Özgüroğlu, Suneel Mundle, Gerhard Leitz, Ute Richarz

Eur J Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W Flaig, Fabio Franke, Suneel D Mundle

Lancet Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Kim N Chi, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Suneel D Mundle

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis